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S U M M A R Y
Background: The impact of Candida-colonized catheter tips in patients without candidemia is unclear.
Methods: A retrospective study of patients with tip cultures positive for Candida was conducted over an
8-year period, to determine the outcomes in patients with Candida cultured from an intravascular
catheter tip in the absence of preceding Candida-positive blood cultures. The primary outcome measure
was deﬁnite candidemia. Secondary outcomes included possible candidemia and in-hospital mortality. A
possible candidemia was deﬁned as clinical signs and symptoms of invasive candidiasis without
explanation other than a candidemia, but with negative blood cultures.
Results: Sixty-eight cultures from 64 patients were included in the study. Deﬁnite candidemia developed
in three cases (4%) and possible candidemia developed in ﬁve cases (7%). In-hospital mortality was
signiﬁcantly increased in patients with deﬁnite or possible candidemia (63% vs. 22%, p = 0.028). Risk
factors for the development of deﬁnite or possible candidemia were catheter time in situ >8 days (odds
ratio (OR) 6.0, 95% conﬁdence interval (CI) 1.1–32.9) and abdominal surgery (OR 6.0, 95% CI 1.1–32.4).
Conclusions: Intravascular catheter tip colonization in patients without preceding blood cultures with
Candida is associated with candidemia in from 4% of patients (deﬁnite candidemia) up to 12% of patients
(deﬁnite and possible candidemia combined). Considering the adverse prognosis associated with delayed
treatment of candidemia, preemptive treatment based on catheter tip cultures might outweigh the
disadvantages of costs and side effects of antifungal therapy.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Candida species are the fourth most common pathogens
isolated from patients with nosocomial bloodstream infections
in the USA and the sixth cause of nosocomial bloodstream
infections in Europe.1–3 The incidence of candidemia in the USA
and Europe varies between 1.9 and 11 per 100 000 inhabitants.4–6
Mortality in patients with candidemia is high, ranging 40% to 60%,
with reported attributable mortality of 20–40%.3 Early initiation of
antifungal therapy in patients with invasive candidiasis has been
demonstrated to be crucial to reduce mortality, but delays in
treatment initiation are common due to the limited sensitivity and§ This paper was presented as an abstract, No. LB-29 ‘‘Candidemic complications
of intravascular catheters colonized with Candida species: an indication for
preemptive antifungal therapy?’’, at the meeting of the Infectious Diseases Society
of America, Philadelphia, USA, October 29–November 1, 2009.
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1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.03.009time-consuming nature of blood cultures, and the lack of speciﬁc
clinical signs.7–10 Hence, prediction rules have been introduced to
identify patients who are at risk of developing candidemia.11–13
Although candidemia is frequently associated with coloniza-
tion of intravascular devices,14,15 the impact of colonization of
an intravascular catheter with Candida in patients without
concomitant candidemia remains undeﬁned. Guidelines for the
management of intravascular catheter-related infections do not
give speciﬁc recommendations for patients with colonized
catheter tips without candidemia because of the lack of clinical
evidence on this subject.16,17 Therefore, this was identiﬁed as an
area for future research by the authors of the guidelines. Studies
in patients with Staphylococcus aureus-colonized catheter tips
have demonstrated subsequent S. aureus bacteremia in 12% to
24% of patients who did not receive antibiotic therapy within 24
or 48 h after catheter removal.18,19 Only one study on the
outcome in patients with Candida cultured from a catheter tip
has recently been performed. In this study, culture-proven
candidemia more than 7 days after catheter removal occurred inses. Published by Elsevier Ltd. All rights reserved.
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dent predictor of a poor outcome.20
The primary aim of this study was to determine the outcomes in
patients with Candida cultured from an intravascular catheter tip
in the absence of preceding Candida-positive blood cultures.
2. Methods
2.1. Study location and patient population
This study was conducted at the University Medical Centre
Utrecht, a tertiary care hospital with 1042 beds in The Netherlands.
All patients with Candida cultured from the tip of an intravascular
catheter between January 2001 and May 2009 were identiﬁed in
the database of the Microbiology Department computer system
(GLIMS version 7.2.4).
2.2. Study design and data collection
A study with a retrospective case–control design was
performed. Culture results of the patients with Candida-
colonized catheter tips were extracted from the database.
Patients with Candida blood cultures within 30 days before
catheter removal were excluded from the analysis. The
following risk factors for candidemia were recorded: admission
to the intensive care unit (ICU), mechanical ventilation,
abdominal surgery during hospital stay prior to catheter
removal, neutropenia, immunosuppressive therapy (e.g., corti-
costeroids and chemotherapy), use of antibacterial therapy 1
week before to 1 week after catheter removal, parenteral
nutrition, co-morbidity, and severity of disease at the time of
admission to the ICU according to the APACHE II classiﬁcation
system (acute physiology and chronic health evaluation score).
The use of antifungal therapy and administration of selective
decontamination of the digestive tract (SDD) were recorded.
SDD has been given to patients in the ICU of our institution since
April 2008 and consists of: local application of polymyxin E,
tobramycin, and amphotericin B in the oropharynx (each in a 2%
concentration, every 6 h) and administration to the stomach
with a nasogastric tube (polymyxin E 100 mg, tobramycin
80 mg, amphotericin B 500 mg) until discharge from the ICU.
Local administration is combined with intravenous cefotaxime
for 4 days.21 In addition, patients with an expected duration of
neutropenia of more than 10 days receive prophylactic
ﬂuconazole therapy.
2.3. Outcome measures
The primary outcome measure was deﬁnite candidemia.
Secondary outcome measures included possible candidemia, in-
hospital mortality, duration of hospital admission, and duration of
ICU admission.
2.4. Deﬁnitions
Deﬁnite candidemia was deﬁned as Candida isolated from
blood cultures taken within 90 days after catheter removal. In
the absence of criteria for possible candidemia, we based a
diagnosis of possible candidemia on the European Organisation
for Research and Treatment of Cancer (EORTC) deﬁnition for
possible invasive fungal disease:22 a host at risk for invasive
candidiasis (neutropenia, persistent fever >96 h refractory to
broad-spectrum antibiotics, graft-versus-host disease, or >3
weeks corticosteroid use), with clinical signs and symptoms of
invasive candidiasis (systemic inﬂammatory response syndrome
that could not be explained otherwise, abscesses in liver orspleen, or retinal exudates) in the absence of any other
explanation for these symptoms and signs, but without a
positive blood culture with Candida spp. After a review of the
medical charts, an expert panel consisting of the authors
decided whether these criteria were met. Catheter exit site
infection was deﬁned as redness, tenderness, swelling, or
purulence at the exit site or obstruction of the catheter.16
Systemic inﬂammatory response syndrome (SIRS) was deﬁned
by the presence of two or more of the following: heart rate >90
beats per min, temperature <36 8C or >38 8C, respiratory rate
>20 breaths per min or arterial partial CO2 pressure <4.3 kPa
and white blood cell count >12  109 cells/l or <4  109 cells/l
or more than 10% immature neutrophils.23 Adequate antifungal
therapy was deﬁned as administration of a systemic antifungal
agent with in vitro activity against the cultured organism after
catheter removal, or administration of a systemic antifungal
agent recommended by the guidelines for the management of
candidiasis if the antifungal susceptibility pattern of the
cultured organism was not determined.24 An adequate dosage
was deﬁned as administration of at least the minimal dose
recommended for treatment of invasive fungal disease.
2.5. Culture technique
Catheter tips were processed as described elsewhere.25 Blood
cultures were incubated for a minimum of 5 days at 35 8C.
2.6. Statistical analysis
Data were analyzed using SPSS for Windows (version 15.0; IBM
SPSS, Chicago, IL, USA). Continuous variables are expressed as
medians and interquartile ranges (p25–p75) or ranges, categorical
variables as number of cases and percentage. Univariate analysis
was performed for comparison of characteristics of patients with
and without deﬁnite or possible candidemia. Signiﬁcance was
assessed with the Student’s t-test for normally distributed
continuous variables and with the Mann–Whitney U-test for
non-parametrically distributed continuous variables. For cate-
gorical variables, signiﬁcance was assessed with Fisher’s exact
test or Pearson’s Chi-square test. Signiﬁcance was assessed two-
sided for all variables. Outcomes with p < 0.05 were considered
signiﬁcant.
3. Results
3.1. Patients
Ninety-four Candida-positive cultures of intravascular catheter
tips were identiﬁed from 88 patients. Twenty-six tip cultures were
excluded because blood cultures were positive with Candida
within 30 days before catheter removal. Sixty-eight cultures
(further referred to as cases) in 64 patients were included in the
analysis. The median age was 59 years (interquartile range 47–71
years) and 62% of the cases were in male patients. Sixty-two (91%)
cases were in patients admitted to the ICU during their hospital
stay; 45 cases (66%) were in patients admitted to the ICU at the
time of catheter removal. The most common co-morbid conditions
were abdominal surgery (38% of cases), malignancy (27%),
hemodialysis (24%), and diabetes mellitus (16%). Immunosuppres-
sive therapy was administered in 34% of the cases. None of the
patients had neutropenia. The majority of cases received antibac-
terial therapy (96%). Systemic antifungal therapy was adminis-
tered in 27 cases (40%) and was initiated a median of 3 days after
catheter removal. The antifungal agent was considered adequate in
all patients who received antifungal therapy. An adequate dosage
Table 1
Characteristics of 68 cases with Candida-colonized catheter tips and their
relationship to culture-proven candidemia
Deﬁnite
candidemia
(n = 3) n (%)
or median
(range)
No deﬁnite
candidemia
(n = 65) n (%)
or median
(range)
Age, years 60 (8–71) 54 (0–82)
Male 2 (67) 40 (62)
Unit at time of catheter removal
ICU 2 (67) 43 (66)
Internal medicine 0 (0) 6 (9)
Surgery 0 (0) 14 (22)
Pediatrics 1 (33) 2 (3)
Admission to ICU 2 (67) 60 (92)
APACHE II 6 (6–6) 25 (11–46)
Co-morbidity
Malignancy 0 (0) 18 (28)
Transplantation 0 (0) 4 (6)
COPD 0 (0) 3 (5)
Diabetes mellitus 1 (33) 10 (15)
Hemodialysis 2 (67) 14 (22)
Abdominal surgery 2 (67) 24 (37)
Mechanical ventilation 2 (67) 48 (74)
Total parenteral nutrition 2 (67) 22 (34)
Neutropenia 0 (0) 0 (0)
Immunosuppressive therapy 1 (33) 22 (34)
Corticosteroids 1 (33) 21 (32)
Chemotherapy 0 (0) 2 (3)
Other 0 (0) 6 (9)
Antibacterial therapy 3 (100) 62 (95)
SDD 0 (0) 9 (14)
SIRS 2 (67) 34 (52)
Systemic antifungal therapy 3 (100) 24 (37)
Total duration, daysa 19 (14–44) 13 (2–41)
Start, days after catheter removala 4 (3–6) 2 (0–9)
Stop, days after catheter removala 25 (17–48) 15 (1–43)
Adequate therapya 3 (100) 24 (100)
Adequate dosea 2 (67) 22 (92)
Candida cultures other sites
beforeb catheter removal
2 (67) 44 (68)
Total number 1 (0–7) 3 (0–11)
Number of sites 1 (0–3) 1 (0–5)
Candida cultures other sites
afterc catheter removal
2 (67) 34 (52)
Total number 6 (0–8) 2 (0–14)
Number of sites 3 (0–5) 1 (0–5)
In-hospital mortality 2 (67) 16 (25)
Length of hospital stay, days 46 (21–90) 52 (7–279)
Length of ICU stay, days 43 (0–69) 17 (0–96)
Categorical variables are expressed as number of cases (percentage); continuous
variables are expressed as median (range). n, number of cases; ICU, intensive care
unit; APACHE II, acute physiology and chronic health evaluation II score; COPD,
chronic obstructive pulmonary disease; SDD, selective decontamination of the
digestive tract; SIRS, systemic inﬂammatory response syndrome.
a In patients receiving systemic antifungal therapy.
b From 30 days before to 1 day after.
c From 2 to 90 days after.
Table 2
Characteristics of 68 catheters and tip cultures in patients with and without
culture-proven candidemia
Deﬁnite
candidemia
(n = 3) n (%)
or median
(range)
No deﬁnite
candidemia
(n = 65) n (%)
or median
(range)
Catheter insertion sitea
Jugular/subclavian 1 (33) 41 (72)
Femoral 2 (67) 12 (21)
Other 0 (0) 4 (7)
Catheter typea
CVC 2 (67) 55 (89)
PICC 0 (0) 1 (2)
Peripheral catheter 0 (0) 2 (3)
Swan–Ganz 0 (0) 3 (5)
Arterial 0 (0) 1 (2)
Portacath 1 (33) 0 (0)
Candida species in
catheter tip culture
Albicans 3 (100) 45 (69)
Glabrata 0 (0) 5 (8)
Parapsilosis 0 (0) 3 (5)
Tropicalis 0 (0) 1 (2)
Not speciﬁed 0 (0) 11 (17)
Candida cfu in catheter tip culture
<10 0 (0) 21 (32)
10–100 1 (33) 38 (59)
>100 2 (67) 6 (9)
Other microorganisms in
catheter tip culture
0 (0) 21 (32)
Catheter exit site infection 2 (67) 8 (12)
Catheter time in situ, daysb 17 (8–665) 8 (1–23)
Time in situ >8 days 2 (67) 21 (38)
Time in situ >10 days 2 (67) 15 (27)
Categorical variables are expressed as number of cases (percentage); continuous
variables are expressed as median (range). n, number of cases; CVC, non-tunneled
central venous catheter; PICC, peripherally inserted central catheter; cfu, colony-
forming units.
a Data missing for eight cases in the ‘No deﬁnite candidemia’ group (n = 57). Three
Swan–Ganz catheters, one arterial catheter, and one totally implantable venous
access system were also located in the jugular or subclavian vein.
b Data missing for 10 cases in the ‘No deﬁnite candidemia’ group (n = 55).
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the different groups of patients can be found in Table 1.
3.2. Catheter and catheter tip culture
The cultured tips derived from: 57 non-tunneled central
venous catheters (28 jugular, 10 subclavian, 14 femoral vein, ﬁve
with unknown insertion site), one peripherally inserted central
catheter, two peripheral catheters, three Swan–Ganz catheters,
one arterial catheter, and one totally implantable venous access
system (portacath). In three cases, both insertion site and type of
catheter are unknown. The catheters had been in situ for a
median duration of 8 days (interquartile range 5–11). Candida
albicans was the most commonly isolated species type (n = 48;
71%). Further details can be found in Table 2.3.3. Outcome
Three cases (4%) with deﬁnite candidemia were identiﬁed after
catheter removal. The time between catheter removal and blood
culture sampling was 5 days in one patient and almost 24 h in two
of these patients. Two of the patients with deﬁnite candidemia
died during hospital admission (67%). Adequate antifungal therapy
was administered in all of the cases with deﬁnite candidemia; it
was initiated 3 to 6 days after the catheter had been removed in
these patients. Detailed characteristics of the patients with deﬁnite
candidemia are presented in Table 3.
An additional ﬁve cases (7%) fulﬁlled the criteria of possible
candidemia. If cases with deﬁnite or possible candidemia were
compared to cases without deﬁnite or possible candidemia,
deﬁnite and possible candidemia was associated with catheter
time in situ >8 days (odds ratio (OR) 6.0, 95% conﬁdence interval
(CI) 1.1–32.9; p = 0.047), abdominal surgery (OR 6.0, 95% CI 1.1–
32.4; p = 0.047), and systemic antifungal therapy (OR 14.0, 95%
CI 1.6–121.8; p = 0.005). Mortality was signiﬁcantly higher in
patients with deﬁnite or possible candidemia (63% vs. 22% of
cases, p = 0.028). There was no signiﬁcant difference in APACHE
II scores between cases with deﬁnite or possible candidemia and
cases without candidemia (21 vs. 25, p = 0.310) and no
signiﬁcant difference in duration of ICU admission or hospital
admission.
Table 3
Characteristics of patients with proven candidemiaa
Pt Age/gender Reason for
admission;
co-morbidity
Abdominal
surgery
Catheter
time
in situ
(days)
Catheter
purpose
Exit
site
infection
Catheter
tip culture
Antifungal therapy Other
medicationc
In-hospital
mortality
Clinical signs
suspect for
disseminated
candidiasis
Other blood cultures Candida
cultures
other sites
before
catheter
removald
Type Duration
(days)
Startb Before
catheter
removald
After catheter
removale
1 8/F Obstructed
portacath;
cystic ﬁbrosis
No 665 Other Yes albicans Fluconazole,
amphotericin
B
30 +4 No No Positive blood
culture with
Candida
albicans
24 h after
catheter
removal
0 0 0 sites
2 71/M Adhesion
ileus with
strangulation;
hemodialysis
Yes 8 TPN,
inotropic
therapy
No albicans Fluconazole 14 +3 No Yes Positive blood
culture
with Candida
albicans
24 h after
catheter
removal
3 neg,
1 CoNS
2 neg 3 sites
3 60/M Urethral
stricture,
diabetes,
mycotic aortic
aneurysm
caused by
E. coli;
hemodialysis
Yes 17 TPN,
inotropic
therapy
Yes albicans Fluconazole 13 +6 Cortico
-steroids
Yes Positive blood
culture with
Candida
albicans 5 days
after catheter
removal
1 neg 3 Enterobacter/
CoNS
/Pseudomonas/
Enterococcus
1 site
Pt, patient; F, female; M, male; TPN, total parenteral nutrition; CoNS, coagulase-negative Staphylococcus; neg, negative.
a All received antibacterial therapy.
b Days after catheter removal.
c Immunosuppressive therapy (corticosteroids, chemotherapy, other) or SDD (selective decontamination of the digestive tract).
d From 30 days before to 1 day after catheter removal.
e From 2 to 90 days after catheter removal.
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This study suggests that in patients without preceding
candidemia, Candida isolated from a catheter tip is associated
with candidemia in a selected number of cases. Candida was
identiﬁed in subsequent blood cultures in 4% of cases with a
positive catheter tip culture. We found no evidence of disseminat-
ed candidiasis such as endocarditis or abscesses, but patients may
have died before these complications were identiﬁed. Unfortu-
nately, routine postmortem examinations were not performed. An
additional 7% of cases fulﬁlled the criteria of possible candidemia.
In these cases, candidemia could not be excluded on reasonable
grounds, so the true incidence of candidemia probably lies
between 4% and 12%.
Our ﬁndings may be important, as the reported mortality of
candidemia is high.3 Immediate treatment with antifungal agents
after positive tip cultures become available should be considered if
a substantial part of patients with positive tip cultures appear to
have a subsequent positive blood culture, even if these blood
cultures are taken within 24 h. In these cases, candidemia might
not be a late complication of catheter tip colonization, but might
possibly already exist at the time of catheter removal. A positive tip
culture with Candida can thus serve as the ﬁrst warning sign of
subsequent candidemia. In our cohort, in-hospital mortality was
67% in patients with deﬁnite candidemia. Although only three
cases were identiﬁed, the mortality was substantially higher as
compared to patients without candidemia. The high mortality
could not be explained by a difference in the severity of illness
itself, because APACHE scores were not signiﬁcantly higher in
these patients.
We also found that in all patients with catheter tips positive for
Candida, antifungal therapy was not initiated before a median of 3
days after catheter removal. Other studies have demonstrated that
a delay of more than 12 h to the start of antifungal therapy after the
ﬁrst positive blood cultures are taken, increases mortality by more
than two-fold. Every subsequent day that antifungal therapy is
delayed increases mortality by 1.5-fold.8,9 This would mean that
starting antifungal therapy preemptively after cultures of catheter
tips become available could potentially halve mortality in a subset
of patients. In our cohort this subset ranges from 4% (patients with
a deﬁnite candidemia) to 12% (patients with a deﬁnite or possible
candidemia) and mortality would be reduced from about 60% to
30%. On the other hand, if all 68 cases with positive catheter tip
cultures had received empirical antifungal therapy, 60 to 65 of the
cases (the cases without possible or deﬁnite candidemia in our
study) would have been treated unnecessarily, with the associated
costs and risks of side effects and microbial resistance.
Several aspects of our study differ from those of previous
studies on this subject. In comparison with a study by Perez-Parra
et al., we identiﬁed more patients with candidemia after removal
of Candida-colonized catheter tips.20 In their study, one out of 58
patients developed candidemia. However, patients with positive
blood cultures within 7 days were excluded and cases with
possible candidemia were not included. If all cases with positive
blood cultures after catheter removal had been included, another
ﬁve patients would have been identiﬁed with candidemia (total
10%), which is comparable to our results. In contrast to their setup,
we chose to include all patients with positive blood cultures after
catheter removal within 90 days of removal, because these
patients are at high risk of complications and death if not treated
promptly.8,9
To interpret the results of our study, several issues need to be
taken into account. The retrospective study design comes with
certain inherent limitations. Notably, in accordance with recent
Infectious Diseases Society of America (IDSA) guidelines, blood
cultures and catheter tip cultures were only performed in the caseof a suspicion of infection.16 Therefore, the results of this study
might not be applicable to a setting where catheter tip cultures are
routinely performed even in the absence of a suspicion of infection.
Another limitation is that only in-hospital data were available for
follow-up. Long-term follow-up might have identiﬁed more
patients with adverse outcomes including mortality and could
have assisted in the differentiation of patients with subsequent
candidemia from patients without candidemia. More complex
relationships between risk factors could not be examined, because
the number of subjects was too small for multivariate analysis.
Likewise, the small number of patients with deﬁnite candidemia
limits the reliability of the results of the univariate analysis that
identiﬁed risk factors for candidemia.
Furthermore, we also performed an analysis that included
patients with possible candidemia. The deﬁnition of possible
candidemia was based on the EORTC criteria for invasive fungal
infections and expert opinion. We are aware that such a deﬁnition
may not be entirely applicable to our population. As sensitivity of
blood cultures is less than 50%,26 this method did allow us to study
the outcome of patients with possible candidemia who otherwise
might not have been identiﬁed as such, because candidemia might
not be identiﬁed in blood cultures due to the limited sensitivity and
previous administration of antifungal agents. The true incidence of
candidemia therefore, probably lies in-between the number of
cases with deﬁnite candidemia and the number of cases with
possible or deﬁnite candidemia. In the analysis including the
possible cases, prolonged catheter placement and abdominal
surgery were associated with candidemia, which is consistent with
previously reported risk factors for candidemia.3,16
Paradoxically, antifungal therapy was also associated with
candidemia. This might be explained by empirical antifungal
therapy given to patients with severe disease unresponsive to
antibacterial therapy or at higher risk for candidemia, but initiated
too late to prevent candidemia or even after candidemia had
already developed. Colonization of multiple sites was not
associated with candidemia, although other studies have demon-
strated a correlation.11,12,27 A reason for this might be that in our
institution, routine surveillance cultures to detect Candida
colonization are only performed in patients admitted to the ICU
and only a few sites are sampled (trachea and rectum). The number
of colonized sites between cases could have been inﬂuenced by
differences in the number of cultured sites.
Larger prospective studies with routinely obtained blood
cultures in patients with positive catheter tip cultures and long-
term follow-up data are needed to assess the need for preemptive
antifungal therapy in patients with Candida-colonized catheter
tips. Randomized studies on this subject will probably never be
performed as antifungal therapy should not be withheld from
severely ill patients with suspected candidemia.
In conclusion, intravascular catheter tip colonization with
Candida in patients without preceding blood cultures with Candida
is associated with proven candidemia in a minority (4%) of cases.
Possibly, up to 12% of cases develop subsequent candidemia, but
because of limitations of the methods used to identify these
additional cases, that number has to be interpreted with caution.
Although candidemia occurs only in a minority of cases, mortality
in patients with candidemia is very high (40–60% of cases in the
literature, 67% in our study) and a delay in starting antifungal
treatment increases mortality. Therefore, considering the adverse
prognosis associated with delayed treatment, preemptive treat-
ment based on catheter tip cultures might outweigh the
disadvantages of costs and side effects of antifungal therapy,
especially if factors that are known to be associated with an
increased incidence of candidemia are present.
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